Cardiac Dimensions secures $53M bringing a new dimension to heart failure treatment
Cardiac Dimensions, a leader in minimally invasive heart failure treatments, raised $53 million in Series E funding to advance its Carillon Mitral Contour System for heart failure treatment and to expand global commercialization efforts.
This funding round builds upon previous successful rounds, including a $35 million Series D funding in January 2023 and a $39 million Series B financing in April 2018. Cardiac Dimensions will utilize the funding to help complete the EMPOWER Trial, a landmark in cardiovascular research that employs a blinded, randomized, sham-controlled methodology to bring the Carillon Mitral Contour System closer to widespread U.S. use.
Headquartered in Kirkland, Cardiac Dimensions is addressing unmet needs in heart failure treatment by focusing on minimally invasive treatments and effective solutions that work with the natural structure and function of the heart.